191 related articles for article (PubMed ID: 21417872)
21. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
[TBL] [Abstract][Full Text] [Related]
22. A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
Wilby KJ
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):281-290. PubMed ID: 29101732
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints.
Kovanda LL; Petraitiene R; Petraitis V; Walsh TJ; Desai A; Bonate P; Hope WW
J Antimicrob Chemother; 2016 Jul; 71(7):1885-91. PubMed ID: 27084921
[TBL] [Abstract][Full Text] [Related]
24. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
Fera MT; La Camera E; De Sarro A
Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
[TBL] [Abstract][Full Text] [Related]
25. Caspofungin therapy in immunocompromised children and neonates.
Somer A; Törün SH; Salman N
Expert Rev Anti Infect Ther; 2011 Mar; 9(3):347-55. PubMed ID: 21417874
[TBL] [Abstract][Full Text] [Related]
26. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
27. The echinocandins: three useful choices or three too many?
Bal AM
Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
[TBL] [Abstract][Full Text] [Related]
28. New generation azole antifungals in clinical investigation.
Girmenia C
Expert Opin Investig Drugs; 2009 Sep; 18(9):1279-95. PubMed ID: 19678798
[TBL] [Abstract][Full Text] [Related]
29. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.
Pfaller MA; Rhomberg PR; Castanheira M
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424
[TBL] [Abstract][Full Text] [Related]
30. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
[TBL] [Abstract][Full Text] [Related]
31. Intravenous isavuconazole can be administered 5 days-a-week. A possibility suggested by a real-life observation.
Castagnola E; Mesini A; Saffioti C; Barco S; Bandettini R; Dallorso S; Carrega G; Miano M; Palmisani E; Dufour C
J Chemother; 2020 Jul; 32(4):217-218. PubMed ID: 32364049
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
[TBL] [Abstract][Full Text] [Related]
33. High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis.
Arsiè E; Piconi S; Iavarone M; Cozzi V; Lampertico P; Cattaneo D
Eur J Clin Pharmacol; 2018 Aug; 74(8):1089-1090. PubMed ID: 29666903
[No Abstract] [Full Text] [Related]
34. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
[TBL] [Abstract][Full Text] [Related]
35. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
[TBL] [Abstract][Full Text] [Related]
36. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
[TBL] [Abstract][Full Text] [Related]
37. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
[TBL] [Abstract][Full Text] [Related]
38. [Invasive aspergillosis in solid organ transplantation].
Silva JT; Torre-Cisneros J; Aguado JM
Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
[TBL] [Abstract][Full Text] [Related]
39. Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
Seyedmousavi S; Verweij PE; Mouton JW
Expert Rev Anti Infect Ther; 2015 Jan; 13(1):9-27. PubMed ID: 25488140
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery.
Knoll BM
J Antimicrob Chemother; 2014 Dec; 69(12):3441-3. PubMed ID: 25114167
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
